

Emily M Hinchcliff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2678868/publications.pdf>

Version: 2024-02-01

29
papers

674
citations

706676

14
h-index

685536

24
g-index

29
all docs

29
docs citations

29
times ranked

1245
citing authors

#	ARTICLE	IF	CITATIONS
1	Discriminatory ability of milestones: An analysis of milestone variability by obstetrics and gynecology subspecialty. <i>Research and Development in Medical Education</i> , 2021, 10, 2-2.	0.2	0
2	Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 19-25.	0.9	8
3	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. <i>Journal of Cancer Education</i> , 2020, , 1.	0.6	1
4	Has dose-dense chemotherapy met an ICONic end?. <i>Lancet Oncology</i> , The, 2020, 21, 869-870.	5.1	1
5	Developmental sacral morphology: MR study from infancy to skeletal maturity. <i>European Spine Journal</i> , 2020, 29, 1141-1146.	1.0	3
6	PARP inhibition in the ovarian cancer patient: Current approvals and future directions. , 2020, 213, 107588.		7
7	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	2.0	16
8	Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. <i>Frontiers in Immunology</i> , 2019, 10, 2410.	2.2	33
9	Comparative Sacral Morphology in Spondylolisthesis Patients. <i>Spine Deformity</i> , 2019, 7, 945-949.	0.7	1
10	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1515-1526.	2.0	14
11	Sunset, or dawn of a new age for ovarian cancer vaccine therapy?. <i>Gynecologic Oncology</i> , 2019, 155, 387-388.	0.6	0
12	An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinum-resistant epithelial ovarian cancer. , 2019, , .		2
13	Disparities in gynecologic cancer genetics evaluation. <i>Gynecologic Oncology</i> , 2019, 153, 184-191.	0.6	56
14	Assessment of treatment factors and clinical outcomes in cervical cancer in older women compared to women under 65 years old. <i>Journal of Geriatric Oncology</i> , 2018, 9, 516-519.	0.5	20
15	Visuospatial Aptitude Testing Differentially Predicts Simulated Surgical Skill. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 1044-1050.	0.3	6
16	Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 148, 168-173.	0.6	14
17	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. <i>Gynecologic Oncology</i> , 2018, 151, 407-413.	0.6	17
18	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. <i>Gynecologic Oncology</i> , 2018, 151, 374-380.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Authors' Response. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 1111.	0.3	0
20	Minimally Invasive Radical Hysterectomy for Cervical Cancer Is Associated With Reduced Morbidity and Similar Survival Outcomes Compared With Laparotomy. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 402-406.	0.3	79
21	Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. <i>Gynecologic Oncology</i> , 2017, 147, 612-616.	0.6	14
22	Laparoscopic Hysterectomy for Uterine Fibroids. <i>Clinical Obstetrics and Gynecology</i> , 2016, 59, 66-72.	0.6	6
23	Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. <i>Gynecologic Oncology</i> , 2016, 143, 236-240.	0.6	97
24	The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 567-572.	0.3	51
25	Racial disparities in survival in malignant germ cell tumors of the ovary. <i>Gynecologic Oncology</i> , 2016, 140, 463-469.	0.6	17
26	Risk Factors for Occult Uterine Sarcoma Among Women Undergoing Minimally Invasive Gynecologic Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 34-39.	0.3	19
27	Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 178-185.	0.7	44
28	Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage MÄ¼llerian cancer. <i>Gynecologic Oncology</i> , 2015, 139, 407-412.	0.6	14
29	The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. <i>Gynecologic Oncology</i> , 2014, 132, 360-365.	0.6	133